By Stefanie Haxel and Anita Greil
DOW JONES NEWSWIRES
BASEL (AFX) – The drugmaker Roche last year on higher volume because of the expenses for the Takeover of California’s Genentech Inc. earned less. The sales increase is 8% to CHF 49.05 billion, as the Roche Holding AG on Wednesday announced. By contrast, net income declined 22% to 8.5 billion Swiss francs. Analysts had on average a profit of C $ 8.22 billion on sales of C $ 49.12 billion forecast.
Operating profit before exceptional items increased in contrast the twelve months increased 8% to 15 billion Swiss francs. Reported by Roche Core earnings per share were 12.19 CHF 10% over the previous year. The dividend for 2009 will be increased by 20% to 6 CHF per share. The Payout ratio for 2010 is to be increased as planned, said CFO Erich Hunziker on Wednesday during a teleconference.
Particularly strong was the largest division Pharma a sales increase of 8% thanks to the influenza medicine "Tamiflu" and the portfolio in the oncology area developed. Of Tamiflu sales last year was dramatically increased after governments around the world the means of protection against pandemics placed orders, including before New A/H1N1-Virus ( "swine flu"). Roche redeemed with the middle C $ 3.2 billion, more than four times the previous year.
The proceeds of the sale are likely to hit song in 2010 but CHF 1.2 billion decrease as the Governments of their stocks now have increased, it said. This estimate is, however, with Involve uncertainty, "said CEO Severin Schwan.
The turnover of the diagnostic activities climbed 2009, at 4%. Both segments – Pharmaceuticals and diagnostics – had grown faster than the market, said Roche on. The Basel pharmaceutical manufacturers also expects for the current fiscal year 2010 for the pharmaceuticals division and the whole group to an average single-digit revenue growth.
With the cancer drug Rituxan, Roche redeemed in the past Years CHF 6.09 billion, an increase of 6%. Avastin breast cancer resources reach sales growth of 21% to 6.22 billion Swiss francs.
According to estimates by analysts, the figures were mixed. While revenues were in line with expectations, disappointed profit. The cost of Genentech were higher integration failed, as expected. On the other hand Roche but also implicitly Outlook raised, "said Karl Heinz Koch, an analyst at the Zurich Broker Helvea AG.
They still expect double-digit growth in core earnings per share 2010, but they do so from a higher vantage point, if Considering that the Tamiflu sales were higher than initially expected, "said Koch. The core recovery is a measure of profitability before non-cash expenses and other Special items and is now used by most pharmaceutical companies.
The shares of Roche tendency on the Zurich Stock Exchange in Morning trading about 1.2% weaker at 178.30 Swiss francs.
- By Stefanie Haxel and Anita Greil, Dow Jones Newswires
+49 (0) 69 29725 100, unternehmen.de @ dowjones.com
DJG / DJN / sha / kla
Visit our website http://www.dowjones.de
(END) Dow Jones Newswires
February 03, 2010 04:53 ET (09:53 GMT)
Copyright (c) 2010 Dow Jones & Company, Inc